Clinical Efficacy of Huangqin Beimutang in Treatment of Chronic Rhinosinusitis in Children
10.13422/j.cnki.syfjx.20231697
- VernacularTitle:黄芩贝母汤治疗儿童慢性鼻-鼻窦炎的临床疗效
- Author:
Xiaoxue SI
1
;
Xue HAN
2
;
Shanshan ZHAO
1
Author Information
1. Medical College of Pediatrics， Henan University of Chinese Medicine，Zhengzhou 450000，China
2. Children's Hospital Affiliated to Zhengzhou University，Zhengzhou 450000，China
- Publication Type:Journal Article
- Keywords:
Huangqin Beimutang;
children;
chronic rhinosinusitis;
efficacy observation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(10):160-165
- CountryChina
- Language:Chinese
-
Abstract:
ObjectTo observe the clinical efficacy of Huangqin Beimutang on chronic rhinosinusitis in children. MethodA randomized controlled trial （RCT） was conducted on 70 children who met the criteria for chronic rhinosinusitis， with 35 cases in the Chinese medicine group and 35 cases in the western medicine group. In the western medicine group，children received mometasone furoate nasal spray，one spray per nostril，once a day for two weeks， and also received a small dose of azithromycin suspension at 4 mg·kg-1·d-1，once a day，3 days a week for 2 weeks. The children in the Chinese medicine group were treated with oral Huangqin Beimutang，one dose per day for 2 weeks. Before and after treatment，the scores of primary symptoms and signs of traditional Chinese medicine （TCM），visual analogue scale （VAS） symptom scores，sinus computed tomography （CT） efficacy scores，and clinical efficacy of TCM syndromes in the two groups were evaluated，and the occurrence of adverse events was recorded. ResultThe total effective rate of clinical efficacy of TCM syndrome in the Chinese medicine group was 88.57% （31/35）， which was higher than 71.43% （25/35） in the western medicine group（χ2=8.458，P<0.05）. The VAS scores， scores of TCM primary symptoms of nasal obstruction and runny nose， and physical sign scores in both groups were lower than those after treatment （P<0.01）. The above indicators in the Chinese medicine group were superior to those in the western medicine group after treatment （P<0.05， P<0.01）. Compared with the conditions before treatment， there was no significant improvement in headache in the western medicine group， while the headache score in the Chinese medicine group decreased after treatment （P<0.01）. The CT scores of the two groups showed a downward trend， but the difference was not statistically significant. There were no adverse reactions during treatment in both groups. ConclusionHuangqin Beimutang can effectively improve the clinical symptoms of patients with chronic rhinosinusitis， and it is safe and effective.
